Global Discovery Biosciences is a pioneer in the field of diagnostic medicine. The company works on the cutting edge of medical research, turns discoveries into innovative products and brings those products to the global marketplace.
The company works with advanced research teams to develop, manufacture and distribute innovative technology platforms to address the needs of the global disease burden. Its CLIA-certified and GMP laboratory performs a menu of clinically effective tests targeting key health issues. Its goal is to equip physicians with the tools they need to transform health care – one patient at a time.
Dr. Douglas Harrington has over 25 years of experience in the research, development, commercialization, and expansion of innovative healthcare technology and services. Dr. Harrington was a member of Dr. Jack Copeland’s, first heart transplant team in Arizona in 1979, and co-founded one of the first clinical molecular biology laboratories in the U.S. with the Nebraska Lymphoma Study Group headed by Dr. Jim Armitage. As former President and Lab Director of Nichols Institute, Dr. Harrington expanded their molecular genetics, infectious disease, immunology, cytogenetic, and anatomic pathology offerings.
Dr. Harrington has developed patents for an automated method for image analysis of residual cancer protein, a patent covering catalytic heavy metal extraction, and a patent pending on biomarker assay for diagnosis and classification of cardiac disease. He has been involved as director or founder of multiple startup companies – from devices to molecular genetics focusing on immunology, cancer and cardiology, where he has taken a number of new molecular technologies through state and federal regulatory approval.
Throughout his career Dr. Harrington has remained a Clinical Professor of Pathology at the USC Keck School of medicine, a published author of numerous peer-reviewed papers, and a sought after speaker in the area of preventive medicine. In addition to being the CEO & Lab Director of Global Discovery Biosciences, Dr. Harrington is also the managing director of TriValley Healthcare in Qatar. Dr. Harrington received his BA in molecular biology, and MD from the University of Colorado at Boulder and is board certified in hematology, anatomic and clinical pathology.
The research behind the test found that the use of nine biomarkers and established clinical risk factors (including diabetic status) correlated with the underlying formation of unstable cardiac lesions proved to significantly improve identification of at-risk patients frequently missed by current methods.
Results demonstrated that the novel protein-biomarker and clinical risk factor algorithm identified patients who went on to experience an acute coronary event. Acute Coronary Syndrome (ACS) is the main cause of coronary artery disease mortality.
Learn more about GD Biosciences:
07/27/2015: Times Colonist – Blood test can assess heart attack risk, conference told
07/27/2015: Saskatoon Star Phoenix – New test for heart attack risk
07/26/2015: The Province – Blood test can assess heart attack risk, Vancouver conference hears
05/19/2015: My Fox Philly – Technology helps predict heart attacks
05/19/2015: KTTV – LA – Technology helps predict heart attacks
05/19/2015: Fox 9 – Technology helps predict heart attacks
05/19/2015: Good Day Austin – Technology helps predict heart attacks
Phone: (888) 399-5534 x7777
Phone: (888) 399-5534 x7778